Suppr超能文献

[腹腔镜诊断胃癌患者术后腹膜转移复发及双向腹腔内与全身化疗的临床疗效]

[Laparoscopic diagnosis of postoperative recurrence of peritoneal metastasis in gastric cancer patients and the clinical efficacy of bidirectional intraperitoneal and systemic chemotherapy].

作者信息

Yan C, Yang Z Y, Shi M, Xu W, Ni Z T, Hua Z C, Liu W T, Zhu Z L, Bi R D, Zheng Y N, Feng R H, Yao X X, Chen M M, Li C, Zhang J, Yan M, Zhu Z G

机构信息

Department of Gastrointestinal Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Stomach Neoplasm, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Department of Gastrointestinal Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Stomach Neoplasm, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China; Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2020 May 25;23(5):492-498. doi: 10.3760/cma.j.cn.441530-20200415-00210.

Abstract

To explore the diagnostic value of laparoscopy in the postoperative recurrence of peritoneal metastasis in gastric cancer, and to investigate the efficacy of bidirectional intraperitoneal and systemic (BIPS) chemotherapy for the recurrence. The descriptive case series study was conducted. Case inclusion criteria: (1) gastric cancer patients without synchronous distant metastasis received D2 radical gastrectomy; (2) postoperative adjuvant chemotherapy was administered; (3) no other distant metastasis except recurrence of peritoneal metastasis; (4) age of 18-75 years; (5) Eastern Cooperative Oncology Group (ECOG) performance-status score≤2; (6) pretreatment evaluation suggested that surgery and chemotherapy could be tolerated. Eight consecutive gastric cancer patients with postoperative recurrence of peritoneal metastasis who met the above criteria at Department of Gastrointestinal Surgery of Ruijin Hospital from September 2015 to September 2016 were enrolled into the study. There were 6 males and 2 females with the median age of 52 (38-68) years. They received laparoscopy or laparotomy first, and then were evaluated with reference to the Sugarbaker peritoneal cancer index (PCI) and the peritoneal metastasis classification of gastric cancer developed by the Japanese Gastric Cancer Research Association. A peritoneal access port was implanted in the subcutaneous space of the lower abdomen and the patients received chemotherapy for 21 days as a course of treatment. All the patients received intraperitoneal 20 mg/m(2) of paclitaxel (PTX) via implanted subcutaneous peritoneal access ports and intravenous 50 mg/m(2) of PTX at day 1 and day 8, meanwhile 80 mg/m(2) of Tigio was orally administered per day for 14 consecutive days, followed by 7 days of interval. Follow-up ended on December 15, 2019. Of these 8 patients with recurrence of peritoneal metastasis after gastric cancer surgery, 1 case underwent laparotomy and loop stoma of terminal ileum because of complete colonic obstruction, and the remaining 7 cases underwent laparoscopy successfully and the recurrence of peritoneal metastasis was clearly diagnosed. Two patients with ovarian metastasis underwent laparoscopic bilateral adnexectomy. The median follow-up time was 17.5 (1.5 to 39.0) months, the median number of BIPS chemotherapy course was 11 (1 to 30), and the median survival time (MST) after BIPS chemotherapy was 17.0 months. The major adverse reaction in BIPS treatment was mainly myelosuppression, of which grade 3/4 leukopenia and neutropenia developed in 1 and 2 cases respectively. No BIPS-related death occurred. The MST of gastric cancer after radical gastrectomy was 40.0 months. Laparoscopy is a safe and feasible method for diagnosing the recurrence of peritoneal metastasis of gastric cancer. BIPS chemotherapy is effective and safe for its treatment and deserves further study.

摘要

探讨腹腔镜检查在胃癌术后腹膜转移复发中的诊断价值,并研究双向腹腔内和全身(BIPS)化疗对复发的疗效。进行描述性病例系列研究。病例纳入标准:(1)无同步远处转移的胃癌患者接受D2根治性胃切除术;(2)术后给予辅助化疗;(3)除腹膜转移复发外无其他远处转移;(4)年龄18 - 75岁;(5)东部肿瘤协作组(ECOG)体能状态评分≤2;(6)预处理评估表明手术和化疗可耐受。2015年9月至2016年9月在瑞金医院胃肠外科连续纳入8例符合上述标准的胃癌术后腹膜转移复发患者。其中男性6例,女性2例,中位年龄52(38 - 68)岁。他们首先接受腹腔镜检查或剖腹手术,然后参照Sugarbaker腹膜癌指数(PCI)和日本胃癌研究协会制定的胃癌腹膜转移分类进行评估。在下腹部皮下空间植入腹腔通路端口,患者接受化疗,21天为一个疗程。所有患者通过植入的皮下腹腔通路端口腹腔内给予20mg/m²紫杉醇(PTX),并在第1天和第8天静脉给予50mg/m² PTX,同时每天口服80mg/m²替吉奥,连续14天,随后间隔7天。随访至2019年12月15日。在这8例胃癌术后腹膜转移复发患者中,1例因完全性结肠梗阻行剖腹手术及回肠末端造口术,其余7例成功接受腹腔镜检查并明确诊断腹膜转移复发。2例卵巢转移患者接受腹腔镜双侧附件切除术。中位随访时间为17.5(1.5至39.0)个月,BIPS化疗疗程中位数为11(1至30),BIPS化疗后的中位生存时间(MST)为17.0个月。BIPS治疗的主要不良反应主要是骨髓抑制,其中3/4级白细胞减少和中性粒细胞减少分别发生1例和2例。未发生与BIPS相关的死亡。根治性胃切除术后胃癌的MST为40.0个月。腹腔镜检查是诊断胃癌腹膜转移复发的一种安全可行的方法。BIPS化疗对其治疗有效且安全,值得进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验